3 results
Approved WMORecruiting
Objectives are to evaluate the efficacy of the procedure in reducing disease specific symptoms such as nasal congestion, rhinorrhea, nasal itching and sneezing, but also to investigate the influence on quality of life, safety and tolerability.
Approved WMOPending
Primary objective:Non-invasively determining the 11C-erlotinib brain uptake in DIPG patients by PET imaging.Secondary objective:Determining the EGFR expression in DIPG
Approved WMOCompleted
Primary:Determine the MTD and/or RDE(s) of ABL001:* As a single agent for CML CP and AP patients* In combination with either nilotinib or imatinib or dasatinib in CML CP and AP patients* As a single agent for CML BP patients and Ph+ ALL…